Can Psychedelic Therapy Go Mainstream?

Summary

Can Psychedelic Therapy Go Mainstream?

In the August 3, 2025 episode of NPR's Up First, titled "Can Psychedelic Therapy Go Mainstream?", host Rachel Carlson delves into the burgeoning field of psychedelic therapy and its potential to revolutionize mental health treatment. This comprehensive exploration addresses the scientific advancements, regulatory challenges, and emerging business models shaping the future of psychedelic substances in therapeutic settings.

---

1. The Current Landscape of Mental Health Treatments

Rachel Carlson opens the discussion by highlighting the pressing need for alternative treatments in mental health care. According to Aisha Rascoe, approximately 13% of Americans over the age of 12 experience symptoms of depression (02:42). A significant portion of these individuals, about one-third, suffer from treatment-resistant depression—conditions where conventional treatments like antidepressants and SSRIs (e.g., Lexapro, Prozac) fail to provide relief (02:42). This gap underscores the demand for innovative therapeutic options.

---

2. Mechanisms of Psychedelic Therapy

Exploring the science behind psychedelics, Rascoe explains that these substances may enhance neuroplasticity, the brain's ability to form new neural connections (03:32). Neuroscientist David Olson from the University of California, Davis, uses a forest metaphor to illustrate this concept:

“Another way I like to think about it is if you have a very rich canopy, squirrels can hop from one tree to the other very easily, just like neuronal impulses can transfer from one cell to the next very easily.” – David Olson, 03:54

In contrast to traditional SSRIs, which often require weeks or months to take effect, psychedelics like MDMA and psilocybin could produce therapeutic benefits within hours or days, lasting for weeks to months after just a single dose (05:07).

---

3. The Psychedelic Renaissance and Regulatory Hurdles

Rascoe refers to the recent surge in interest and research as a "psychedelic renaissance". Despite promising developments, psychedelic substances remain illegal under federal law, classified as Schedule I by the DEA, and are not approved by the FDA for medical use (06:05). This legal status poses significant barriers to widespread clinical adoption and research advancements.

However, there has been a shift in federal sentiment. U.S. Health Secretary Robert F. Kennedy, Jr. expressed intentions to expedite the approval process for psychedelic treatments, signaling potential regulatory progress (01:39).

---

4. The Controversial Role of the Psychedelic "Trip"

A central challenge in integrating psychedelics into mainstream therapy is the psychedelic experience, often characterized by hallucinations and altered states of consciousness, colloquially known as a "trip" (08:13). While therapeutic benefits are promising, the unpredictable and intense nature of these experiences raises concerns:

“Tripping can be dangerous, especially for some people, like people who have bipolar disorder or schizophrenia. The trip can make those conditions worse.” – Aisha Rascoe, 08:59

This aspect complicates the feasibility of using psychedelics in everyday medical practice, where patients are expected to resume normal activities post-treatment.

---

5. Insights from the Heifetz Study: Rethinking Therapeutic Factors

David Olson spearheaded an innovative study aimed at isolating the pharmacological effects of psychedelics by eliminating the subjective psychedelic experience. By administrating ketamine—a substance similar to psychedelics but classified as a Schedule III drug—in a controlled, unconscious state during routine surgeries, Olson sought to determine if the drug alone could alleviate depression symptoms (12:18).

Unexpectedly, the results revealed that both the ketamine and placebo groups experienced significant improvements in depression, with no distinguishable difference between them:

“They were indistinguishable from the patients who got ketamine. So that was a surprise and actually very difficult for us to wrap our heads around.” – David Olson, 16:09

This finding suggests that non-pharmacological factors—such as patient expectations, hope, and the therapeutic setting—may play a critical role in the efficacy of psychedelic treatments.

---

6. The Rise of At-Home Ketamine Therapy

In response to regulatory barriers, companies like Mindbloom have emerged, offering at-home ketamine therapy as an alternative to traditional clinical settings (21:31). Mindbloom's model involves:

1. Initial Psychiatric Evaluation: Conducted virtually by a licensed clinician to assess eligibility.
2. Prescription Fulfillment: Ketamine is delivered directly to the patient's home.
3. Guided Sessions: Patients use a kit containing tools like an eye mask and blood pressure cuff, and are supported by digital tools such as an app with soundscapes and journaling prompts (22:21).

While this approach increases accessibility and reduces costs—offering sessions for $150 to $200 compared to clinic-based treatments that can cost up to $1,000 per session—it raises safety concerns. Potential adverse effects of ketamine include dizziness, nausea, increased blood pressure, and severe medical emergencies like stroke or heart attack (23:35).

Dr. Gerald Bush from the American Psychiatric Association emphasizes these risks, highlighting the lack of immediate medical support and consistent safety standards in at-home settings (24:50).

In response, Mindbloom outlines stringent safety protocols, including medical screening, supervised first sessions via Zoom, and mandatory presence of an adult peer monitor during administrations to manage emergencies (25:01).

“Not all ketamine therapy programs are created equal and its protocols are developed by leading experts in psychiatry.” – Mindbloom Representative, 25:01

---

7. Weighing the Benefits Against the Risks

The episode concludes by acknowledging the dual-edged nature of psychedelic and ketamine therapies. While offering hope to individuals with limited treatment options, these therapies come with significant risks and uncertainties:

“It's honestly still a really hard question to answer because in my reporting, I talk to all of these people who are weighing the serious risks and serious benefits of these drugs in really different ways.” – Aisha Rascoe, 26:33

Patients like Cindy Dahlman report feeling a profound sense of joy post-treatment, yet remain uncertain about the exact cause of their improvement—whether it was the drug, the therapeutic environment, or their mindset (27:15).

“I still felt joyful inside.” – Cindy Dahlman, 27:33

---

8. The Road Ahead for Psychedelic Therapy

As psychedelic therapy navigates the intricate balance between potential and peril, ongoing research and regulatory developments will be pivotal. The Heifetz study, in particular, invites the scientific community to reassess the essential components of successful therapy—suggesting that factors beyond chemical intervention may be equally, if not more, important.

With companies like Mindbloom pioneering accessible treatment models and federal attitudes beginning to shift, the mainstream adoption of psychedelic therapy remains promising yet contingent on addressing safety, efficacy, and regulatory compliance.

---

This episode of Up First underscores the transformative potential of psychedelic therapy in mental health care while meticulously examining the complexities that accompany its integration into mainstream medicine. For listeners seeking to understand the future of mental health treatments, Carlson's in-depth reporting offers a balanced and insightful perspective.

Transcript

[Aisha Rascoe]

Aisha.

[Rachel Carlson]

I'm Aisha Rascoe, and this is a Sunday story from up first, where we go beyond the news of the day to bring you one big story. Today we're going to take a trip through the world of psychedelics. Now, for me, that word makes me think of party drugs like LSD and ecstasy and magic mushrooms. You know, people going on a trip, far out. But in the last few decades, there's been a surge of research showing that psychedelics can help with mental health conditions that can be very hard to treat, like ptsd, depression, addiction. Still, there are major obstacles to the widespread use of psychedelics, including the fact that they're illegal under federal law and that doctors can't prescribe them. Last summer, it seemed like there might finally be an opening for psychedelics to become a part of the medical mainstream. The FDA reviewed its first official application for a psychedelic treatment, a version of ecstasy known as mdma, to treat ptsd. But the FDA ultimately rejected the application, citing flawed data and questionable research. This was a sign for many people in the industry that it could be years before psychedelic treatments would be federally approved. But a couple of months ago, the federal government changed its tune. U.S. health Secretary Robert F. Kennedy, Jr. Recently told members of Congress that he wants to expedite the approval of psychedelic treatments.

[David Olson]

This line of therapeutics has tremendous advantage if given in a clinical setting, and we are working very hard to make sure that that happens within 12 months.

[Rachel Carlson]

Joining us now is NPR's Rachel Carlson. She's a producer on our science podcast Short Wave. Today on the Sunday story, Rachel takes us through the current state of psychedelics research from neuroscientists who are working to overcome obstacles to the use of these drugs in therapy to a company that's found another to increase access by turning to the drug ketamine. Rachel, welcome to the podcast.

[Aisha Rascoe]

Hi, Ayesha. Thank you.

[Rachel Carlson]

So, Rachel, before we get into the science of how psychedelics work to possibly treat depression, ptsd, anxiety, and more, I want to ask probably like a very basic, maybe simple question. What's wrong with our current treatments for depression and ptsd? Why do we have to look into psychedelics?

[Aisha Rascoe]

Honestly, Aisha, I don't think that's a basic question at all. And I think the answer really comes down to the fact that there's not necessarily anything wrong with the treatments that we have now. It's that there's this big need for alternatives. One estimate from the CDC shows around 13% of Americans over the age of 12 have symptoms of depression. So that's one in eight people. People. And at least a third of those people have depression. That's considered treatment resistant, which means the treatments we have now, like antidepressants or SSRIs, just don't work for them. So that's a lot of people who really need a different option.

[Rachel Carlson]

So how do psychedelics work in the brain? Like, how are they different from SSRIs, like Lexapro or, you know, Prozac or something like that.

[Aisha Rascoe]

So right now, researchers think psychedelics work by increasing something called neuroplasticity. And I talked to one neuroscientist about this.

[Boris Heifetz]

My name's David Olson, and I'm a chemical neuroscientist.

[Aisha Rascoe]

He researches psychedelics at the University of California, Davis. And Olson used this metaphor I've come across a few times, which is that the neurons in the human brain are kind of like trees.

[Boris Heifetz]

It really does look like the arbors of trees.

[Aisha Rascoe]

And just like in a healthy forest, where the trees are thick with branches and leaves, a healthy brain is buzzing. It's full of growth connections. Think of a forest in spring. It's lush, active. Everything's working together. Here's Olson.

[Boris Heifetz]

Another way I like to think about it is if you have a very rich canopy, squirrels can hop from one tree to the other very easily, just like neuronal impulses can transfer from one cell to the next very easily.

[Aisha Rascoe]

But when people have conditions like depression.

[Boris Heifetz]

It looks like wintertime. You know, all the leaves have fallen off the trees, and now there's not that physical connectivity between adjacent neurons and.

[Aisha Rascoe]

That lack of connectivity within the brain, some research suggests that it can have an effect on mood. So existing treatments like SSRIs, you mentioned Lexapro, Prozac, those can also help these connections regrow. But they can often take weeks or even months to make a difference if people respond to them at all. So when it comes to psychedelics, the idea is that they could make this happen in a matter of hours or.

[Boris Heifetz]

Days and produce therapeutic effects that can last for weeks to months after just a single dose.

[Rachel Carlson]

I mean, that seems like a really big deal, especially if you're struggling with depression.

[Aisha Rascoe]

It is. It's a really big deal. And I will say a lot of this research is happening on animals, and researchers think something similar is happening in humans. So there's a lot more that needs to be understood. But as much of this research was picking up in the early 2000s, Olson told me these discoveries led to a kind of paradigm shift for modern psychiatry.

[Boris Heifetz]

And neuroscience, because it was moving us, you know, more towards a healing based approach where if you take a drug once or a few times, that could lead to long lasting therapeutic benefit. So now you're not thinking about taking a drug every single day for the rest of your life.

[Aisha Rascoe]

In the last several years, there's been even more excitement around psychedelics as a therapy, so much so that a lot of people are calling this a psychedelic renaissance. But Aisha, you mentioned before, one of the biggest obstacles to more research and use of psychedelics is, is they're illegal things like psilocybin, LSD, MDMA. These are all categorized as Schedule 1 substances by the DEA, which means they're among the most highly restricted drugs in the country and illegal under federal law. And as of today, none of them have been FDA approved for any kind of medical use. There are ongoing clinical trials, but right now psychedelics aren't available in most doctors offices.

[Rachel Carlson]

When we come back, what will it take for psychedelics, psychedelics to show up in doctor's offices? Rachel tells us about two neuroscientists who have tried to figure that out by taking the trip out of psychedelics.

[Cindy Dahlman]

This message comes from Schwab. Everyone has moments when they could have done better, like cutting their own hair or forgetting sunscreen. So now you look like a tomato. Same goes for where you invest. Level up and invest smarter with Schwab. Get market insights, education and human help when you need it.

[Dylan Bynon]

Learn [e-mail] this message comes from Mattress Firm. Tossing, turning and waking up drenched, sleeping hot can ruin your night and leave you feeling off the next day too. Mattress Firm can help you finally cool things down. Their sleep experts will match you to the right cooling mattress. Like the Tempur Breeze, this collection has advanced technology to deliver unmatched cooling comfort for deeper Z's. For the great sleep you deserve, visit Mattress Firm and upgrade to cooling comfort. They make sleep easy. This message comes from NPR sponsor Odoo. Some describe Odoo like a magic beanstalk because it scales with you and is magically affordable. Odoo, exactly what a business needs. Sign [e-mail] that's o d o o.com.

[Rachel Carlson]

We'Re back with the Sunday story. So Rachel, let's talk about the trip. You know, so far we've talked about the neurological side of psychedelics. But the trip that, you know, the hallucinations that out of body experience, that's the thing that I think most people probably think about when you bring up psychedelics, right?

[Aisha Rascoe]

Totally. And this question is also kind of at the heart of what's going on in the science of psychedelics therapy now because that trip can kind of be a problem when it comes to getting psychedelics to go mainstream.

[Rachel Carlson]

I mean, I would imagine, you know, people can't just be tripping all over the place. But, but, but how specifically? Like what are the specific risks?

[Aisha Rascoe]

I mean, tripping can be dangerous, especially for some people, like people who have bipolar disorder or schizophrenia. The trip can make those conditions worse. And you probably don't really want to or shouldn't do things like go to work while you're tripping. So it gets in the way of day to day activities. Basically it adds another layer of risk for drugs like psychedelics. So while scientists are seeing a lot of potential here, some have started to wonder how important this whole trip is and if people could get those same benefits in their brains without tripping at all.

[Rachel Carlson]

But what are psychedelics without the triple that?

[Aisha Rascoe]

Such a good question. And if you remember David Olson, he's the chemical neuroscientist at UC Davis, this is what he told me.

[Boris Heifetz]

We need to have something that is so safe that you can simply pick it up at your local pharmacy, bring it home and put it in your medicine cabinet.

[Rachel Carlson]

So he wants this to be like a regular antidepressant that you just run out to CVS or to Walgreens and then you just take it home.

[Aisha Rascoe]

Yeah, he's thinking about this from a pharmaceutical perspective where you just take a pill and you go about your day to day life. He co founded a company called Delix Pharmaceuticals where he's trying to engineer drugs like psychedelics to remove the trip.

[Rachel Carlson]

So how do you take a psychedelic and engineer the trip out of it?

[Aisha Rascoe]

Olson told me it's kind of like playing with molecular bricks of Lego.

[Boris Heifetz]

When we optimize their structures, we, we don't change them too radically. We just move things around a little bit here and there, make them better versions of themselves.

[Aisha Rascoe]

So Olson thinks this method could be one way to give more people access to the potential benefits of drugs like psychedelics. Although I should say that while delegates pharmaceuticals early research is promising. There's definitely more research that they'll need to do. In the meantime, Aisha, I want to tell you about another scientist I spoke to who's also interested in removing the trip from psychedelics, but with a bit of a different perspective. He wants to improve the research behind why these drugs work the way they do.

[Rachel Carlson]

Okay, how is he doing that?

[Aisha Rascoe]

Let me start with a little bit of context, because there's this problem that's plagued psychedelic Research, basically, since its inception, and that's that when scientists want to prove that a drug or treatment actually works the way they want it to, they usually set up what's called a controlled study, so that they can say that the treatment or the drug is what's really working on people and not something else.

[Rachel Carlson]

So it's not the placebo effect.

[Aisha Rascoe]

Exactly. So in a controlled study, one group gets the drug or treatment, and another group gets a placebo. And it's really important that neither group knows which one they're in. But in a psychedelic study, this is actually very hard to do, because if.

[Rachel Carlson]

You take the drug and you start to feel like you're floating, you know you got the real stuff, right?

[Aisha Rascoe]

Yeah. If you're tripping, if you're stuck seeing things, you're gonna know that you didn't get a placebo. And that's a really big problem for the whole industry. Let me introduce you to Boris Heifetz. He's a neuroscientist and anesthesiologist at Stanford. He's been working on a solution to this big problem.

[David Olson]

So a lot of people actually have been talking about this for years, like, well, what if you just knock someone out?

[Aisha Rascoe]

So his idea is that you could put everyone in the study to sleep and then administer the drug or placebo. And he was like, I'm an anesthesiologist. I can do that.

[David Olson]

So I found myself with a particular niche that I was very excited to fill.

[Rachel Carlson]

So tell me more about this study. Like, how did he pull this off?

[Aisha Rascoe]

So in this study, Heifetz worked with 40 people who were all diagnosed with major depression. And all of those people were also scheduled to have some kind of routine surgery for where they were gonna go under general anesthesia. So the participants go in for their surgeries, they get their general anesthesia, they go to sleep, and then they're either given an infusion of the drug or placebo. And the drug Heifetz was testing was ketamine.

[Rachel Carlson]

Now, why ketamine? Like, is that a psychedelic?

[Aisha Rascoe]

So, technically, ketamine's not a psychedelic. But if you remember how researchers think psychedelics could help regrow the neurons in the brain, kind of like those trees in a healthy forest, and how that may help treat conditions like depression. Scientists think that ketamine might have a similar effect on the brain. So Heifetz is interested in understanding psychedelics more broadly. But ketamine's long been used medically as an anesthetic, and It's a Schedule 3 drug, so it's a little bit easier to study.

[Rachel Carlson]

So what did he find out?

[Aisha Rascoe]

Something he really did not expect. But before I tell you about that, I want to introduce you to one of the patients in his study.

[Gerald Bush]

Hi, my name is Cindy Dahlman.

[Aisha Rascoe]

When she agreed to do this study, Dahlman was in her late 50s and scheduled for an appendix surgery. But she'd also been dealing with depression for pretty much her entire life and said she was at a particularly low point.

[Gerald Bush]

I'm from Santa Cruz. Life should be wonderful at the beach, right? But it wasn't in my head, and I just fell into a depressed spiral.

[Aisha Rascoe]

So as part of the study, she went in for her surgery like normal.

[Gerald Bush]

I was nervous, I was still depressed, but I was feeling hopeful.

[Rachel Carlson]

So what happened when she woke up?

[Aisha Rascoe]

Here's what she told me.

[Gerald Bush]

It was like the next day that I really felt the overall, oh, this is. Something's different. You know, I did have a little bit of a bluebird on the windowsill kind of feeling the joyfulness of more awareness of the presence of the day around me and not just the funk in my head.

[Rachel Carlson]

Did she actually get the ketamine?

[Aisha Rascoe]

Yeah, she did. But remember when she got it, she was under anesthesia, so she had no idea. And Heifetz told me that in Dahlman's.

[David Olson]

Group, the patients who got ketamine came in with depression and got a lot better. 50 to 60% of our patients saw a halving of a symptom load. 30% met criteria for remission from treatment resistant depression. I mean, who wouldn't be happy with that result?

[Aisha Rascoe]

And then Heifetz told me about a different patient who also had depression.

[David Olson]

She, this was like her, you know, nth, like fifth, like cancer surgery. Like this had been a recurrent cancer. She been through the wringer.

[Aisha Rascoe]

He saw this other patient a couple of days after her surgery.

[David Olson]

She was almost like dancing. This is, you know, someone who had, like a lot of stuff in their belly, like still had drains, bandages. I thought to myself at the time, like, if she didn't get ketamine, like, I'm quitting.

[Rachel Carlson]

So this woman was definitely not in the placebo group, right? Or did. Did he have to quit?

[Aisha Rascoe]

Right? He didn't quit, but she was in the placebo group.

[Rachel Carlson]

That. That's mind blowing. What's, how's this happening?

[Aisha Rascoe]

No, it' super confusing. Like, I was confused when I first read the study. Heifetz told me he was confused because statistically, when they looked at the results, everyone in the study got better. The ones who got ketamine and the ones who were in the placebo group.

[David Olson]

They were indistinguishable from the patients who got ketamine. So that was a surprise and actually very difficult for us to wrap our heads around.

[Rachel Carlson]

Okay, well that's a trip right there. Where does that leave Heifetz then?

[Aisha Rascoe]

So I mean, I guess just to preface this, it's one study, it was 40 patients. But Heifetz told me that the findings of the study made him think a lot about the importance of all the parts of psychedelic or ketamine therapy that aren't the drug. It's what he calls the non drug.

[David Olson]

Factors like hope, expectations and integrating change, like that's all that's what drove this big therapeutic effect.

[Rachel Carlson]

So the experience around taking the drug clearly matters.

[Aisha Rascoe]

At least that's what Heifetz told me he took away from this study, that the experience around the drug is hugely important for healing and that includes things like therapy, support systems and even the expectations a patient has. It's not just chemical. Heifetz told me his discovery points to a need to see psychedelics holistically.

[Rachel Carlson]

So there are lots of questions that researchers are still grappling with to make psychedelics safer and more understood. But while they're doing this research, ketamine is already going mainstream and companies are facilitating sending it straight to people's homes. More on that after the break.

[Dylan Bynon]

Support for NPR and the following message come from Goodrx. School's back and so are the germs. Thankfully there's Goodrx. With Goodrx you can find big savings at the pharmacy all year round. Compare prescription prices at over 70,000 pharmacies and instantly find discounts of up to 80%. GoodRx is not insurance, but it may beat your co pay if you do have insurance. Get simple smart savings on back to school [e-mail] upfirst this message comes from.

[Cindy Dahlman]

Fisher Investments Senior Vice President Michael Hosmar shares one way their fiduciary fiduciary duty comes to life when working with clients.

[Aisha Rascoe]

We listen to our clients goals, their.

[Rachel Carlson]

Objectives, their personal needs and we build.

[Aisha Rascoe]

A plan that puts their needs first. They want to know what we're truly thinking about how that thinking is being built into our plan for them because that's how seriously we take our fiduciary responsibility.

[Cindy Dahlman]

Learn [e-mail] Investing in securities involves the risk of loss.

[Dylan Bynon]

This message comes from Progressive Insurance. Do you ever think about switching insurance companies to see if you could save some cash? Progressive makes it easy to see if you could save when you bundle your home and auto policies. Try [e-mail], progressive Casualty Insurance Company and affiliates. Potential savings will vary. Not available in all states.

[Rachel Carlson]

We're back with the Sunday story. So, Rachel, before we get into at home ketamine therapy, let's talk more about ketamine and what it is for a second and help me to understand like, just how similar is it to a psychedelic.

[Aisha Rascoe]

So people can still get kind of like a trippy feeling, but it really depends on how much a person takes. So it could feel like anything from being a little bit drunk to a complete dissociative experience. So someone might feel like they're separated from their own body and it lasts anywhere from 45 minutes to 2 hours versus something like LSD, which might last at least most of a person's day. And technically speaking, it's not considered a psychedelic at all because scientists think that ketamine works by binding to a different receptor in the brain. But the key thing with ketamine when it comes to people actually using it for mental health conditions is it's currently way more accessible to patients. Doctors can legally prescribe ketamine right now. In fact, there's one FDA approved version of ketamine to treat depression. It's a nose spray called Spravato. It's like a chemical cousin of ketamine. And patients have to take it in a doctor's office under medical supervision. But because ketamine is already legal as an anesthetic, doctors can also prescribe it through something called off label use. So that's when they'll prescribe a drug for something that it hasn't been specifically approved to treat. And this is a pretty common practice. In this case, it means they can prescribe things like ketamine injections and lozenges for a variety of conditions, including things like anxiety, depression or ptsd. And that's kind of how in the last few years ketamine has really burst onto the scene.

[Rachel Carlson]

Right. I mean, I've heard a lot about ketamine in the news with people like Elon Musk, who has said he's used prescription ketamine in the past.

[Aisha Rascoe]

Yes. It's been all over the news. And this was interesting to me because a lot of people sort of lump it into the same bucket as psychedelics. And there are these companies that will even facilitate sending ketamine directly to your home.

[Rachel Carlson]

So tell me about one of these companies.

[Aisha Rascoe]

One of those companies is called Mindbloom. I wanted to talk to Them because it's the largest at home ketamine therapy provider in the United States. So I talked to the founder and CEO, Dylan Bynon.

[Cindy Dahlman]

We provide at home ketamine therapy for people with anxiety, depression and ptsd. And we've brought the cost down to make it affordable for everyday Americans.

[Aisha Rascoe]

So, Aisha, if a person goes to a clinic and gets a dose of ketamine there, the cost of sessions can range a lot, but they can get up to about $1,000 each. People also need to get someone to drive them to and from their treatment, maybe take time off of work to do that. But if they go through Mind Bloom, their website says that a session for new clients can range from 150 to $200, and their clients do their treatment at home.

[Rachel Carlson]

Okay, so. So walk me through, like, how this process works.

[Aisha Rascoe]

Yeah. So for Mind Bloom, they start with a psychiatric evaluation. This happens virtually. A licensed clinician meets with a client on a video call and goes through their medical and psychiatric history, and they'll determine their diagnosis and make sure that the patient is eligible for ketamine therapy. And if they're cleared to receive treatment, the clinician who works with Mindbloom will write a prescription for ketamine, and that prescription is then fulfilled by a pharmacy that delivers the ketamine straight to the client's home. What they also get in the mail is a whole kit that includes things like an eye mask, a blood pressure cuff, and a journal. And Bynon also told us that Mindbloom has an app that clients download with things like Soundscape's and journaling prompts.

[Cindy Dahlman]

And then after their sessions are going to integrate. And so after everybody's session, they voice journal into the app and they get integration tips and practices for how they can really make changes in their life while they're in this neuroplastic state.

[Rachel Carlson]

I mean, this sounds almost like a self care routine, but it's a powerful drug. Are there still some things that could go wrong?

[Aisha Rascoe]

Absolutely. Ketamine can make people feel dizzy, nauseous, panicked. It can also increase their blood pressure, and it could induce more serious side effects like a stroke or a heart attack or heart arrhythmia. I do want to make clear that Mindbloom is far from the only company involved in sending ketamine to people's homes. In the last few years, there have been at least a dozen companies popping up that provide this service. And some medical professionals have started to express concern about this growing industry as a whole. The FDA, for example, issued a statement in 2023, specifically warning that using ketamine at home without monitoring from a health care professional comes with serious risks. And when I heard this, I also wanted to reach out to the American psychiatric association, the APA, for another perspective. I got an email back from Dr. Gerald Bush, who works on the Council on Addiction Psychiatry, and he wrote that they have significant safety concerns about at home ketamine therapy. His main concern is that there's not immediate medical help if something does happen at a patient's home. He's also worried that the at home industry doesn't have regulatory oversight when it comes to things like consistent safety and dosing standards.

[Rachel Carlson]

So how does Mindbloom, for example, manage all these risks when their clients take ketamine at home or without a doctor present?

[Aisha Rascoe]

I asked them this question and this is what they told me. They said, quote, not all ketamine therapy programs are created equal and its protocols are developed by leading experts in psychiatry. They also pointed me to two peer reviewed studies, including one they published last year that had over 11,000 of their clients. One of the key findings they highlighted there is that fewer than 5% of those clients reported any adverse effects. They also walked us through their safety protocols. So before clients start treatment, Mindbloom says they screen for medical conditions, and for the first session, they take the ketamine with a company trained guide on Zoom. This guide serves as kind of a facilitator or coach for the client's experience, but they're not a medical provider. Before and after each session, clients monitor their own heart rate and blood pressure with a cuff the company provides. And Mindbloom also requires clients to have an adult nearby each time they take the ketamine. That's what they call a peer treatment monitor. So if something does go wrong and it's minor, that person's instructed to reach out to Mindbloom's on call clinician. But if it's a medical emergency, they're told to call 911.

[Rachel Carlson]

So, Rachel, it's clear through all of this that there are people who are really enthusiastic about what psychedelic therapy and ketamine could do. And then there are other others who are, they're sort of pumping the brakes a little. When you take a step back, how do you see it?

[Aisha Rascoe]

It's honestly still a really hard question to answer because in my reporting, I talk to all of these people who are weighing the serious risks and serious benefits of these drugs in really different ways. So on the one hand, clearly people need access to new treatment options, and they need those options soon. Ketamine and psychedelics are promising. On the other hand, these are all really powerful drugs and there are risks to using them. But some patients have decided that that risk might be worth it. Cindy Dahlman, for example, the patient in Boris Heifet's study who received ketamine still isn't totally sure if the drug is what made her feel better.

[Gerald Bush]

I went in overall, just hopeful, you know. So did I play a part in that was it mindset? Was it ketamine? I don't know.

[Aisha Rascoe]

But what she does know is that something made a difference.

[Gerald Bush]

I still felt joyful inside.

[Rachel Carlson]

Well, Rachel, thank you for bringing us this very significant reporting on psychedelics and ketamine. This just seems so important because it could really change people's lives.

[Aisha Rascoe]

Yeah. Thanks, Aisha.

[Rachel Carlson]

This episode was produced by Kim Naderfeh Petersa and edited by Justine Yan. Reporting for this episode was brought to you by NPR shortwave podcast. Rebecca Ramirez and Jeff Brumfield edited the original series. Fact checking help from Tyler Jones. Mastering by Kwesi Lee. Thanks also to Micah Ratner. The Sunday Story team includes Andrew Mambo, Jenny Schmidt, and our senior supervising producer, Liana Simstrom. Andrew Sirulnyk is our fellow. Irene Noguchi is our executive producer Producer. I'm Aisha Rascoe. Up first is back tomorrow with all the news you need to start your week. Until then, have a great rest of your weekend.

[Dylan Bynon]

This message comes from Mint Mobile. If you're tired of spending hundreds on big wireless bills, bogus fees and free perks, Mint Mobile might be right for you with plans starting from 15 bucks a month. Shop plans [e-mail] Switch upfront payment of 45 dollars for 3 month 5GB plan required. New customer offer for first 3 months only. Then full price plan options available. Taxes and fees extra. See Mint Mobile for details. This message comes from Bombas. Socks, underwear and T shirts are the top three requested clothing items by people experiencing homelessness. Bombas makes all three and donates one item for every item purchased. Go to bombas.com NPR and use code NPR for 20% off. This message comes from Mint Mobile. If you're tired of spending hundreds on big wireless bills, bogus fees and free perks, Mint Mobile might be right for you with plans starting from 15 bucks a month. Shop plans [e-mail] Switch upfront payment of $45 for 3 month, 5GB plan required. New customer offer for first 3 months only. Then full price plan options available. Taxes and fees extra. See Mint Mobile for details.